Incyte Corp. Urges Federal Circuit to Uphold Sun Pharma Alopecia Drug Injunction

Incyte Corp. has appealed to the Federal Circuit to maintain an injunction that a New Jersey judge implemented in November against Sun Pharmaceutical’s launch of the alopecia medication Leqselvi. Incyte argues that the initial ruling was justified, claiming that the release of the drug would grant Sun an unreasonable “head start” in the market, thus impacting competitive balance. For further details, more information is available on Law360.